drugset / Trial / NCT01042535
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
Phase 1/2
Completed
44 enrolled
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This randomized phase I/II trial studies the side effects and best dose of vaccine therapy and to see how well it works when given together with 1-methyl-D-tryptophan (1-MT) in treating patients with metastatic breast cancer. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.
Timeline
- Start
- 2009-12-28
- Primary completion
- 2014-12-01
- Completion
- 2018-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Indoximod | Small molecule | — | Oral |
| Subject | adenovirus-p53 transduced dendritic cell (DC) vaccine | Vaccine | — | Other |